Latest Information Update: 18 May 2000
At a glance
- Originator Allergan
- Class Antiglaucomas
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 18 May 2000 Discontinued-II for Glaucoma in USA (Ophthalmic)
- 08 Jul 1997 New profile
- 08 Jul 1997 Phase-II clinical trials for Glaucoma in USA (Ophthalmic)